EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library Primary sources and pharmacopeia-grade databases Schematics, not to scale

Brain, nerves and neurotransmitters

How the nervous system is organized, how one neuron passes a chemical signal to the next, which enzymes make and remove each neurotransmitter, and what decides whether a compound in the blood reaches the brain. Each value is tied to the source it came from.

86.1 billionneurons in the adult male human brain on average (± 8.1 billion), with 84.6 billion non-neuronal cells
19%of the brain's neurons are in the cerebral cortex, which makes up 82% of brain mass
≈99%of the outer surface of brain capillaries is covered by astrocyte endfeet
67 µMplasma caffeine estimated to occupy half of human brain A1 adenosine receptors, from PET in 15 men

Azevedo FAC, et al. J Comp Neurol 2009;513:532–541; Kadry H, Noorani B, Cucullo L. Fluids Barriers CNS 2020;17:69; Elmenhorst D, et al. J Nucl Med 2012;53:1723–1729.

Status. Education, not medical advice. EUTECNIQ is in formation and has no laboratory, studies or clinical data. Schematics are drawn for this page and are not to scale; the caffeine occupancy curve is an educational calculation, not a measurement or a prediction for any product.

Related: ADME, PK and PBPK · Blood–brain barrier property rules · Bioactive compounds · Proteins, peptides and collagen

Organization

The brain and spinal cord are the central nervous system; every nerve and ganglion outside them is peripheral

The central nervous system (CNS) is the brain and spinal cord. The peripheral nervous system (PNS) is everything else: nerves, which are bundles of axons, and ganglia, which are clusters of nerve-cell bodies. By function, the PNS has a somatic division for conscious perception and voluntary movement, an autonomic division for smooth muscle, heart muscle and glands, and an enteric division in the wall of the gut.

Three peripheral divisions, two of them involuntary; the autonomic division splits into sympathetic and parasympathetic partsTextbook classification
Organization of the nervous system: the central nervous system is the brain and spinal cord; the peripheral nervous system has somatic, autonomic and enteric divisions; the autonomic division has sympathetic and parasympathetic partsNervous systemSensation, integration andresponseCentral nervous system (CNS)Brain and spinal cord. In the CNS, axon bundlesare tracts and cell-body clusters are nucleiBrain86.1 ± 8.1 billionneurons in the adultmale brainSpinal cordLateral horns holdthe autonomicpreganglionicneuronsPeripheral nervous system (PNS)Nerves (axon bundles) and ganglia (cell-body clusters) outsidethe brain and spinal cordSomaticConscious perception andvoluntary motorresponsesAutonomicInvoluntary control ofsmooth muscle, cardiacmuscle and glandsEntericSmooth muscle and glandsof the digestive system; notdependent on the brain andspinal cordSympatheticPreganglionic neurons inthe thoracic and upperlumbar cordParasympatheticPreganglionic neurons inbrainstem nuclei and thesacral cordOrganization of the nervous system as an indented treeNervous systemSensation, integration and responseCentral nervous system (CNS)Brain and spinal cord. In the CNS, axon bundles aretracts and cell-body clusters are nucleiBrain86.1 ± 8.1 billion neurons in the adult male brainSpinal cordLateral horns hold the autonomic preganglionicneuronsPeripheral nervous system (PNS)Nerves (axon bundles) and ganglia (cell-body clusters)outside the brain and spinal cordSomaticConscious perception and voluntary motorresponsesAutonomicInvoluntary control of smooth muscle, cardiacmuscle and glandsSympatheticPreganglionic neurons in the thoracic and upperlumbar cordParasympatheticPreganglionic neurons in brainstem nuclei andthe sacral cordEntericSmooth muscle and glands of the digestive system;not dependent on the brain and spinal cord
OpenStax Anatomy and Physiology 2e, §12.1 and §15.1 (2022). Neuron count: Azevedo et al. 2009.
Explanation, details and sources
  • Central nervous system. Brain and spinal cord. Regions rich in cell bodies and dendrites are gray matter; regions rich in myelinated axons are white matter. In the CNS a cluster of cell bodies is a nucleus and a bundle of axons is a tract.
  • Peripheral nervous system. Structures outside the brain and spinal cord. A cluster of cell bodies is a ganglion and a bundle of axons is a nerve.
  • Somatic division. Conscious perception and voluntary motor responses.
  • Autonomic division. Involuntary control of smooth muscle, cardiac muscle and glands, mainly for homeostasis. Sympathetic preganglionic neurons sit in the lateral horn of the thoracic and upper lumbar spinal cord; parasympathetic preganglionic neurons sit in brainstem nuclei and the lateral horn of the sacral cord.
  • Enteric division. Controls the smooth muscle and glands of the digestive system, is counted as part of the PNS and is not dependent on the brain and spinal cord. Its myenteric plexus, between the longitudinal and circular muscle layers, coordinates movement; its submucosal plexus, nearer the mucosa, regulates secretion.

OpenStax Anatomy and Physiology 2e, §12.1 and §15.1; Walsh KT, Zemper AE. Cell Mol Gastroenterol Hepatol 2019;8:369–378; Tobias A, Sadiq NM. Physiology, Gastrointestinal Nervous Control. StatPearls, updated September 26, 2022.

Every autonomic preganglionic fiber releases acetylcholine; the postganglionic transmitter is what differsTextbook physiology
Autonomic pathways: every preganglionic fiber releases acetylcholine onto nicotinic receptors; parasympathetic postganglionic fibers release acetylcholine onto muscarinic receptors; most sympathetic postganglionic fibers release norepinephrine onto adrenergic receptors; the adrenal medulla releases epinephrine and norepinephrine into the bloodDivision and originPreganglionic fiber, ganglion, postganglionic fiberTarget and its receptorParasympatheticBrainstem nuclei (cranial nerves III, VII,IX, X) and sacral cordPreganglionic cell body in the CNSTerminal or intramural ganglionAChnicotinicTerminal or intramuralganglionAChSmooth muscle, cardiac muscle,glandsmuscarinicSympatheticLateral horn, thoracic and upper lumbarcordPreganglionic cell body in the CNSChain (paravertebral) or collateral (prevertebral) ganglionAChnicotinicChain (paravertebral) or collateral(prevertebral) ganglionNEMost sympathetic targetsα- and β-adrenergicSympathetic, exceptionLateral horn, thoracic and upper lumbarcordPreganglionic cell body in the CNSChain ganglionAChnicotinicChain ganglionAChSweat glands; blood vessels ofskeletal muscleAdrenal medullaLateral horn, thoracic and upper lumbarcordPreganglionic cell body in the CNSAChAdrenal medullavia bloodEpinephrine, norepinephrineReleased into the bloodstreamAutonomic pathways, one panel per divisionParasympatheticBrainstem nuclei (cranial nerves III, VII, IX, X) and sacralcordAChTerminal or intramural ganglionnicotinicAChSmooth muscle, cardiac muscle, glandsmuscarinicSympatheticLateral horn, thoracic and upper lumbar cordAChChain (paravertebral) or collateral (prevertebral)ganglionnicotinicNEMost sympathetic targetsα- and β-adrenergicSympathetic, exceptionLateral horn, thoracic and upper lumbar cordAChChain ganglionnicotinicAChSweat glands; blood vessels of skeletal muscleAdrenal medullaLateral horn, thoracic and upper lumbar cordAChAdrenal medullaEpinephrine, norepinephrineReleased into the bloodstream
OpenStax Anatomy and Physiology 2e, §15.1 (2022). Ganglion position is drawn to show that sympathetic chain ganglia lie beside the spinal cord and parasympathetic terminal ganglia lie near or within the target organ.

All ganglionic neurons carry nicotinic receptors; parasympathetic targets carry muscarinic receptors; most sympathetic targets carry α- and β-adrenergic receptors.

Text version of the autonomic chains
  • Parasympathetic. Preganglionic neurons in brainstem nuclei (axons in cranial nerves III, VII, IX and X) and the sacral cord release acetylcholine (ACh) onto nicotinic receptors in terminal or intramural ganglia. Postganglionic fibers release ACh onto muscarinic receptors of smooth muscle, cardiac muscle and glands.
  • Sympathetic. Preganglionic neurons in the thoracic and upper lumbar cord release ACh onto nicotinic receptors in chain (paravertebral) or collateral (prevertebral) ganglia. Postganglionic fibers release norepinephrine (NE) onto α- and β-adrenergic receptors.
  • Sympathetic exception. Postganglionic fibers to sweat glands and to blood vessels of skeletal muscle release ACh.
  • Adrenal medulla. Receives sympathetic preganglionic fibers and releases epinephrine and norepinephrine into the bloodstream.
Cells

The human brain holds about 86 billion neurons and a similar number of other cells, not ten times more glia

Counts by the isotropic fractionator, which dissolves tissue into a suspension of nuclei and counts neuronal nuclei by their NeuN marker, put the adult male brain at 86.1 ± 8.1 billion neurons and 84.6 ± 9.8 billion non-neuronal cells. The cerebellum holds most of the neurons; the cerebral cortex holds most of the other cells.

The cerebellum has 69 billion of the brain's 86 billion neurons; the cerebral cortex has more non-neuronal cells than neuronsPublished measurements
Neurons and non-neuronal cells in the adult male human brain by region, in billions, measured with the isotropic fractionatorNeurons (NeuN-positive)Non-neuronal cellsWhole brainWhole brain: 86.1 billion neurons86.1Whole brain: 84.6 billion non-neuronal cells84.6Cerebral cortex (gray and whitematter)Cerebral cortex (gray and white matter): 16.34 billion neurons16.34Cerebral cortex (gray and white matter): 60.84 billion non-neuronal cells60.84CerebellumCerebellum: 69 billion neurons69Cerebellum: 16 billion non-neuronal cells16020406080100Billions of cellsNeurons and non-neuronal cells in the adult male human brain by region, in billions, measured with the isotropic fractionatorNeurons (NeuN-positive)Non-neuronal cellsWhole brainWhole brain: 86.1 billion neurons86.1Whole brain: 84.6 billion non-neuronal cells84.6Cerebral cortex (gray and white matter)Cerebral cortex (gray and white matter): 16.34 billion neurons16.34Cerebral cortex (gray and white matter): 60.84 billion non-neuronal cells60.84CerebellumCerebellum: 69 billion neurons69Cerebellum: 16 billion non-neuronal cells16020406080100Billions of cells
Azevedo et al., J Comp Neurol 2009 (whole brain, adult men); regional values as tabulated from Azevedo et al. in von Bartheld CS, Bahney J, Herculano-Houzel S. J Comp Neurol 2016;524:3865–3895, Tables 1 and 4. Cortex values include white matter.
Show data: neurons and non-neuronal cells by region
Neurons and non-neuronal cells in the adult male human brain, billions
RegionNeurons, billionsNon-neuronal cells, billionsSource
Whole brain86.1 ± 8.184.6 ± 9.8Azevedo et al. 2009, abstract
Cerebral cortex, gray and white matter16.3460.84von Bartheld et al. 2016, Table 1
Cerebellum6916von Bartheld et al. 2016, Table 4

The review that compiled 150 years of counts concluded that histology always supported a glia-to-neuron ratio of about 1:1 for the whole human brain, with 40–130 billion glial cells. The often-repeated figure of one trillion glial cells and a 10:1 ratio is not supported by the original data.

Neuron shapes and glial cell types, where they occur and what they do
Cell typeWhereWhat it does
Multipolar neuronCNS and PNS; most neuronsOne axon and two or more dendrites
Bipolar neuronMainly olfactory epithelium and retinaOne axon and one dendrite
Unipolar (pseudo-unipolar) neuronSensory neurons with cell bodies in gangliaOne process that includes both the axon and the dendrite
AstrocyteCNSSupport; maintains extracellular chemical concentrations; contributes to the blood–brain barrier
OligodendrocyteCNSMyelinates CNS axons
MicrogliaCNSImmune surveillance and phagocytosis
Ependymal cellCNSMakes cerebrospinal fluid
Satellite cellPNS: sensory and autonomic gangliaSupports neuron cell bodies
Schwann cellPNS: peripheral nervesMyelinates one segment of one axon

OpenStax Anatomy and Physiology 2e, §12.2 (2022); von Bartheld et al. 2016, abstract.

Synapse

At a chemical synapse an electrical signal becomes a chemical one, and the signal ends when the transmitter is removed

A neuron releases transmitter from vesicles when calcium enters its terminal. The transmitter diffuses across the synaptic cleft and binds receptors on the next cell. Uptake transporters and enzymes then clear it, which sets how long the signal lasts.

Release, receptor binding and removal at one chemical synapseSchematic, not to scale
Chemical synapse: transmitter release, receptors, reuptake and enzymatic inactivation, schematic and not to scaleAxonCleftPostsynaptic cellAstrocyte12345678991An action potential reaches the presynaptic axonterminal (top).2Voltage-gated Ca²⁺ channels open and Ca²⁺ entersthe terminal.3Vesicular transporters (VGLUT, VGAT, VAChT,VMAT2) load transmitter into vesicles, driven by theproton gradient of the vesicular proton pump.4Ca²⁺ triggers vesicle fusion; transmitter is releasedby exocytosis and diffuses across the cleft.5Ionotropic receptor: a ligand-gated ion channel; fasttransmission on a millisecond time scale.6Metabotropic receptor: acts through a G protein, aneffector protein and second messengers.7Reuptake into the terminal by Na⁺-coupledtransporters: DAT, NET, SERT, GAT1, GlyT2.8Uptake into nearby glia (for example glutamate byEAATs).9Enzymes end the signal: AChE in the cleft; MAO-Aand MAO-B on the mitochondrial outer membrane.Chemical synapse, schematic and not to scale, with a numbered keyAxonCleftPostsynaptic cellAstrocyte12345678991An action potential reaches the presynaptic axonterminal (top).2Voltage-gated Ca²⁺ channels open and Ca²⁺ enters theterminal.3Vesicular transporters (VGLUT, VGAT, VAChT,VMAT2) load transmitter into vesicles, driven by theproton gradient of the vesicular proton pump.4Ca²⁺ triggers vesicle fusion; transmitter is released byexocytosis and diffuses across the cleft.5Ionotropic receptor: a ligand-gated ion channel; fasttransmission on a millisecond time scale.6Metabotropic receptor: acts through a G protein, aneffector protein and second messengers.7Reuptake into the terminal by Na⁺-coupledtransporters: DAT, NET, SERT, GAT1, GlyT2.8Uptake into nearby glia (for example glutamate byEAATs).9Enzymes end the signal: AChE in the cleft; MAO-A andMAO-B on the mitochondrial outer membrane.
Sequence: OpenStax Anatomy and Physiology 2e, §12.5. Transporters and enzymes: UniProt entries SLC17A7 (VGLUT1), SLC32A1 (VGAT), SLC18A3 (VAChT), SLC18A2 (VMAT2), SLC6A3 (DAT), SLC6A2 (NET), SLC6A4 (SERT), SLC6A1 (GAT1), SLC6A5 (GlyT2), ACHE, MAOA, MAOB. The cleft width is not drawn to a measured scale.

Ionotropic receptors are ligand-gated ion channels that mediate fast transmission on a millisecond time scale; metabotropic receptors act through G proteins, effector proteins and second messengers.

Explanation, details and sources
  1. ArrivalAn action potential reaches the presynaptic terminal and opens voltage-gated Ca²⁺ channels; Ca²⁺ enters.
  2. LoadingVesicular transporters fill vesicles using the proton gradient made by the vesicular proton ATPase: VGLUT for glutamate, VGAT for GABA and, to a lesser extent, glycine, VAChT for acetylcholine and VMAT2 for dopamine, norepinephrine, epinephrine, serotonin and histamine. VGAT, VAChT and VMAT2 exchange transmitter for protons; VGLUT works mainly as a uniporter driven by the electrical part of the gradient.
  3. ReleaseCa²⁺ helps the vesicle merge with the membrane; transmitter is released by exocytosis and diffuses across the cleft.
  4. ReceptorsEach receptor is specific for its transmitter. Ionotropic receptors are ligand-gated ion channels; metabotropic receptors are G protein–coupled and act through effector proteins and second messengers.
  5. RemovalNa⁺-coupled plasma-membrane transporters take transmitter back into the terminal: DAT (dopamine), NET (norepinephrine), SERT (serotonin), GAT1 (GABA) and GlyT2 (glycine). Amino-acid transmitters are also taken up by nearby glia; EAAT2 carries each glutamate with two or three Na⁺ ions.
  6. EnzymesAcetylcholinesterase hydrolyzes acetylcholine in the cleft. Monoamine oxidases A and B, on the outer mitochondrial membrane, deaminate monoamines; catechol O-methyltransferase, in soluble and membrane-bound forms, methylates catecholamines. Neuropeptides are cut into inactive fragments by peptidases.

OpenStax Anatomy and Physiology 2e, §12.5 and Table 12.3; Concise Guide to PHARMACOLOGY 2023/24: Ion channels (millisecond time scale); UniProt (accessed October 29, 2026): Q9P2U7, Q9H598, Q16572, Q05940, Q01959, P23975, P31645, P30531, Q9Y345, P43004, P22303, P21397, P27338, P21964; Purves D, et al., eds. Neuroscience, 2nd ed. 2001, “Peptide Neurotransmitters.”

Neurotransmitters

Each neurotransmitter has its own synthesis enzymes, receptor families and route of removal

Small-molecule transmitters are amino acids, amines, purines, lipids and one gas. Neuropeptides are cut from larger precursor proteins. Receptor names below follow the IUPHAR/BPS nomenclature published in the Concise Guide to PHARMACOLOGY.

Five transmitters act on ion channels as well as G protein–coupled receptors; the amines, lipids and peptides act almost only on G protein–coupled receptorsIUPHAR/BPS nomenclature
Receptor families for each neurotransmitter, divided into ionotropic (ligand-gated ion channel) and metabotropic (G protein-coupled) receptors, with nitric oxide acting on soluble guanylyl cyclaseTransmitterIonotropic (ligand-gated ion channel)Metabotropic (G protein-coupled)OtherGlutamateAMPA: GluA1–4Kainate: GluK1–5NMDA: GluN1, GluN2A–D, GluN3A–BmGlu1–mGlu8GABAGABAA​: pentamers; α1–6, β1–3, γ1–3, δ, ε, θ, π,ρ1–3GABAB​: GABAB1​ + GABAB2​GlycineGlyR: α1–α3 with β (α4 a human pseudogene)NMDA receptor co-agonist (GluN1 site)AcetylcholineNicotinic: pentamers; α1–7, α9–10, β1–4, γ, δ, εM1–M5 (muscarinic)DopamineD1, D2, D3, D4, D5noneNorepinephrine, epinephrineα1A, α1B, α1Dα2A, α2B, α2Cβ1, β2, β3noneSerotonin (5-HT)5-HT3 (5-HT3A–E subunits)5-HT1A, 1B, 1D, 1e, 1F5-HT2A, 2B, 2C5-HT4, 5A, 6, 7HistamineH1, H2, H3, H4noneAdenosineA1, A2A, A2B, A3noneATPP2X1–P2X7 (trimers)P2Y1, 2, 4, 6, 11, 12, 13, 14Anandamide, 2-AGCB1, CB2noneNitric oxideSoluble guanylyl cyclase (makes cGMP)noneSubstance PNK1 (substance P most potent), NK2, NK3noneOpioid peptidesμ, δ, κ; NOP (nociceptin)noneOrexin-A, orexin-BOX1, OX2noneOxytocin, vasopressinOT; V1A, V1B, V2noneNeuropeptide YY1, Y2, Y4, Y5 (y6 not functional in primates)noneReceptor families for each neurotransmitter, phone layoutIonotropic (ligand-gated ion channel)Metabotropic (G protein-coupled)OtherGlutamateAMPA: GluA1–4Kainate: GluK1–5NMDA: GluN1, GluN2A–D, GluN3A–BmGlu1–mGlu8GABAGABAA​: pentamers; α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3GABAB​: GABAB1​ + GABAB2​GlycineGlyR: α1–α3 with β (α4 a human pseudogene)NMDA receptor co-agonist (GluN1 site)AcetylcholineNicotinic: pentamers; α1–7, α9–10, β1–4, γ, δ, εM1–M5 (muscarinic)DopamineD1, D2, D3, D4, D5Norepinephrine, epinephrineα1A, α1B, α1Dα2A, α2B, α2Cβ1, β2, β3Serotonin (5-HT)5-HT3 (5-HT3A–E subunits)5-HT1A, 1B, 1D, 1e, 1F5-HT2A, 2B, 2C5-HT4, 5A, 6, 7HistamineH1, H2, H3, H4AdenosineA1, A2A, A2B, A3ATPP2X1–P2X7 (trimers)P2Y1, 2, 4, 6, 11, 12, 13, 14Anandamide, 2-AGCB1, CB2Nitric oxideSoluble guanylyl cyclase (makes cGMP)Substance PNK1 (substance P most potent), NK2, NK3Opioid peptidesμ, δ, κ; NOP (nociceptin)Orexin-A, orexin-BOX1, OX2Oxytocin, vasopressinOT; V1A, V1B, V2Neuropeptide YY1, Y2, Y4, Y5 (y6 not functional in primates)
Alexander SPH, et al. The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors. Br J Pharmacol 2025;182 Suppl 1:S24–S151; 2023/24: Ion channels. Br J Pharmacol 2023;180 Suppl 2:S145–S222. Lower-case names (5-ht1e, y6) follow the Guide; the y6 gene is a pseudogene in primates. Nitric oxide: Garthwaite J. Eur J Neurosci 2008;27:2783–2802.
Neurotransmitters: chemical class, synthesis with enzyme EC numbers and cofactors, receptor families, inactivation and main roles
TransmitterChemical classPrecursor and synthesisReceptorsInactivationMain roles, as sourced
GlutamateAmino acidFrom glutamine by glutaminase (GLS, EC 3.5.1.2); loaded into vesicles by VGLUTIonotropic: AMPA (GluA1–4), kainate (GluK1–5), NMDA (GluN1, GluN2A–D, GluN3A–B). Metabotropic: mGlu1–8Uptake by Na⁺-coupled EAATs into neurons and glia; in brain, glutamine synthetase (EC 6.3.1.2) converts it to glutamineMain excitatory transmitter of the brain; its receptors cause depolarization
GABAAmino acidFrom glutamate by glutamate decarboxylase GAD65 or GAD67 (EC 4.1.1.15; cofactor PLP); vesicles via VGATGABAA: anion-selective channels assembled from 19 reported subunits. GABAB: GABAB1 + GABAB2 G protein–coupled dimerReuptake by GAT1 (Na⁺, Cl⁻); GABA transaminase (EC 2.6.1.19; PLP)Inhibitory; GABAA receptors mediate fast synaptic and sustained tonic inhibition in the CNS
GlycineAmino acidSerine and glycine are interconverted by PLP-dependent serine hydroxymethyltransferase (SHMT1, EC 2.1.2.1); VGAT also loads glycineGlyR anion channels: α1–α3 with β (α4 is a human pseudogene). Also a co-agonist at the GluN1 site of NMDA receptorsGlyT1 and GlyT2 (Na⁺, Cl⁻)Inhibitory transmission in the spinal cord and brainstem, including motor reflex circuits and synapses onto pain-sensing neurons
AcetylcholineCholine esterCholine + acetyl-CoA by choline acetyltransferase (ChAT, EC 2.3.1.6); choline enters by CHT1; vesicles via VAChTNicotinic pentamers from 16 mammalian subunits (α1–7, α9–10, β1–4, γ, δ, ε); adult muscle type (α1)2β1δε. Muscarinic M1–M5Acetylcholinesterase (EC 3.1.1.7) in the cleftSomatic neuromuscular junction; all autonomic preganglionic fibers; parasympathetic postganglionic fibers
DopamineCatecholamineL-tyrosine → L-DOPA by tyrosine hydroxylase (TH, EC 1.14.16.2; BH4, Fe²⁺; rate-limiting) → dopamine by aromatic L-amino acid decarboxylase (AADC, EC 4.1.1.28; PLP); vesicles via VMAT2D1, D2, D3, D4, D5 (all G protein–coupled)DAT; MAO-A and MAO-B (EC 1.4.3.4); COMT (EC 2.1.1.6)Motivation, reward and reinforcement; coordination of body movements; substantia nigra dopamine neurons degenerate in Parkinson's disease
NorepinephrineCatecholamineDopamine → norepinephrine by dopamine β-hydroxylase (DBH, EC 1.14.17.1; Cu, ascorbate, O2)α1A, α1B, α1D; α2A, α2B, α2C; β1, β2, β3NET; MAO-A; COMTTransmitter of most sympathetic postganglionic fibers; from the locus coeruleus, influences sleep and wakefulness, attention and feeding behavior
EpinephrineCatecholamineNorepinephrine → epinephrine by phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28; S-adenosylmethionine)Same adrenoceptors as norepinephrineMAO; COMTHormone of the adrenal medulla, released with norepinephrine into the blood; CNS neurons in two groups in the rostral medulla
Serotonin (5-HT)IndoleamineL-tryptophan → 5-hydroxytryptophan by tryptophan hydroxylase TPH1 or TPH2 (EC 1.14.16.4; BH4, Fe²⁺; rate-limiting) → serotonin by AADC (PLP)Ionotropic 5-HT3. G protein–coupled: 5-HT1A, 1B, 1D, 1e, 1F, 5-HT2A, 2B, 2C, 5-HT4, 5-HT5A, 5-HT6, 5-HT7SERT; MAO-A, which preferentially oxidizes serotoninMade by neurons of the raphe region of the pons and upper brainstem; implicated in sleep and wakefulness. Precursor of melatonin in the pineal gland
HistamineImidazole amineL-histidine → histamine by histidine decarboxylase (HDC, EC 4.1.1.22; PLP)H1, H2, H3, H4Histamine N-methyltransferase (HNMT, EC 2.1.1.8; S-adenosylmethionine); methylhistamine is a MAO-B substrateMade by hypothalamic neurons; central histamine projections mediate arousal and attention; mast-cell histamine acts in allergic reactions
Adenosine and ATPPurinesExtracellular ATP → AMP by ectonucleoside triphosphate diphosphohydrolase 1 (CD39, EC 3.6.1.5) → adenosine by ecto-5′-nucleotidase (CD73, EC 3.1.3.5)Adenosine: A1, A2A, A2B, A3. ATP: ionotropic P2X1–7; G protein–coupled P2Y1, 2, 4, 6, 11, 12, 13, 14Adenosine: ENT1 transport; adenosine deaminase (EC 3.5.4.4); adenosine kinase (EC 2.7.1.20)Adenosine is a neuromodulator; caffeine's stimulating effects at common doses come from blocking adenosine receptors
AnandamideLipid: N-acylethanolamineFrom membrane N-acyl-phosphatidylethanolamines; NAPE-PLD (EC 3.1.4.54) is one route, mainly yielding saturated and monounsaturated acylethanolamines in brainCB1, CB2; some cannabinoids also engage TRP channels and PPARsFatty acid amide hydrolase (FAAH, EC 3.5.1.99)Endocannabinoid system: CNS development, synaptic plasticity and responses to insults
2-Arachidonoylglycerol (2-AG)Lipid: monoacylglycerolFrom arachidonoyl-containing diacylglycerol by diacylglycerol lipase α (DAGLα, EC 3.1.1.116; Ca²⁺)CB1, CB2Monoacylglycerol lipase (MAGL, EC 3.1.1.23); FAAH also hydrolyzes itRetrograde suppression at central synapses
Nitric oxideGasL-arginine → NO + L-citrulline by neuronal NO synthase (nNOS, EC 1.14.13.39; NADPH, O2, BH4, FAD, FMN, heme), activated by Ca²⁺/calmodulinNO-sensitive (soluble) guanylyl cyclase, which makes cGMPConsumed rapidly as it diffuses through tissue (shown in brain slices)Formed after NMDA receptor activation; changes neuronal excitability and synaptic strength, acting pre- or postsynaptically
Substance PPeptide, 11 amino acidsCut from the TAC1 precursorNK1 (substance P most potent), NK2, NK3PeptidasesSensory transmitter in the spinal cord; involved in the perception of pain; present at high concentrations in parts of the brain and in the gut
Opioid peptidesPeptides: endorphins, enkephalins (Met-enkephalin, 5 amino acids), dynorphins (dynorphin A, 17)Three precursor genes: proopiomelanocortin (POMC), proenkephalin (PENK), prodynorphin (PDYN)μ, δ, κ; nociceptin acts at NOPPeptidasesPerception of pain; in general they tend to be depressants
Orexin-A, orexin-BPeptides, 33 and 28 amino acidsBoth cut from prepro-orexin (HCRT)OX1, OX2PeptidasesMade by neurons in and around the lateral and posterior hypothalamus (rat); stimulate feeding when given into rat brain (animal finding). All six human narcolepsy brains examined in one study showed a global loss of these peptides (hypocretins)
OxytocinPeptide, 9 amino acidsMade by paraventricular hypothalamic neurons; stored in posterior pituitary terminalsOT receptorPeptidasesUterine contraction and cervical dilation; milk ejection reflex
Vasopressin (antidiuretic hormone)Peptide, 9 amino acidsMade by supraoptic hypothalamic neurons; stored in posterior pituitary terminalsV1A, V1B, V2PeptidasesRaises renal water reabsorption; constricts blood vessels at very high concentrations
Neuropeptide YPeptide, 36 amino acidsCut from the NPY precursorY1, Y2, Y4, Y5PeptidasesCentrally promotes feeding and reduces energy expenditure
Sources for the table, row by row

Enzymes, EC numbers, cofactors, reactions and transporter functions: UniProtKB/Swiss-Prot human entries, accessed October 29, 2026: GLS O94925, GLUL P15104, GAD1 Q99259, GAD2 Q05329, ABAT P80404, SHMT1 P34896, CHAT P28329, ACHE P22303, TH P07101, DDC P20711, DBH P09172, PNMT P11086, TPH1 P17752, TPH2 Q8IWU9, AANAT Q16613, ASMT P46597, HDC P19113, HNMT P50135, MAOA P21397, MAOB P27338, COMT P21964, ENTPD1 P49961, NT5E P21589, ADA P00813, ADK P55263, SLC29A1 Q99808, NAPEPLD Q6IQ20, FAAH O00519, DAGLA Q9Y4D2, MGLL Q99685, NOS1 P29475, SLC17A7 Q9P2U7, SLC32A1 Q9H598, SLC18A3 Q16572, SLC5A7 Q9GZV3, SLC18A2 Q05940, SLC6A1–SLC6A5 and SLC6A9, SLC1A2 P43004. Peptide lengths: UniProt peptide features of TAC1 P20366, PENK P01210, PDYN P01213, HCRT O43612, OXT P01178, AVP P01185, NPY P01303.

Receptors: Concise Guide to PHARMACOLOGY 2025/26 (G protein-coupled receptors) and 2023/24 (Ion channels), Br J Pharmacol.

Roles: glutamate, GABA and glycine as excitatory or inhibitory: OpenStax §12.5 and UniProt GLS; GABAA: Concise Guide 2023/24; glycine: Lynch JW. Physiol Rev 2004;84:1051–1095; acetylcholine: OpenStax §15.1 and Concise Guide (muscle type); dopamine, norepinephrine, epinephrine, serotonin, histamine: Purves et al., Neuroscience 2nd ed. 2001, “The Biogenic Amines”; MAO substrates: StatPearls, Monoamine Oxidase Inhibitors (MAOIs), updated December 13, 2025; adenosine: Elmenhorst et al. 2012; endocannabinoids: Lu H-C, Mackie K. Biol Psychiatry 2016;79:516–525 and UniProt DAGLA; nitric oxide: Garthwaite 2008; substance P and opioid peptides: Purves et al., “Peptide Neurotransmitters”; orexins: Sakurai T, et al. Cell 1998;92:573–585 and Peyron C, et al. Nat Med 2000;6:991–997; oxytocin and vasopressin: OpenStax §17.3; neuropeptide Y: Tatemoto K. PNAS 1982;79:5485–5489 and Loh K, Herzog H, Shi Y-C. Trends Endocrinol Metab 2015;26:125–135.

Pathways

Most small-molecule transmitters are one to four enzyme steps from an amino acid, and several steps need vitamin-derived cofactors

Tyrosine, tryptophan, histidine, glutamine and arginine are amino acids; choline is a nutrient. The decarboxylases and transaminases need pyridoxal 5′-phosphate (PLP), an active coenzyme form of vitamin B6. The two rate-limiting hydroxylases use tetrahydrobiopterin (BH4) and iron, and the methyltransferases use S-adenosylmethionine (SAM).

Six pathways from precursor to transmitter, with the enzyme and cofactors of every stepUniProt reactions and cofactors
Synthesis pathways of the main small-molecule neurotransmitters with the enzyme and cofactors for each stepDietary or metabolic precursorNeurotransmitter or hormoneIntermediate or inactive productCatecholaminesL-TyrosineTH, rate-limitingBH4​, Fe2+​, O2​L-DOPAAADCPLP (vitamin B6 form)DopamineDBHCu, ascorbate, O2​NorepinephrinePNMTSAMEpinephrineSerotonin and melatoninL-TryptophanTPH1, TPH2, rate-limitingBH4​, Fe2+​, O2​5-HTPAADCPLPSerotoninAANATacetyl-CoAN-AcetylserotoninASMTSAMMelatoninGABAL-GlutamineGlutaminase (GLS)L-GlutamateGAD65, GAD67PLPGABAGABA-TPLPSuccinicsemialdehydeAcetylcholineCholine +acetyl-CoAChATAcetylcholineAChEin the cleft; choline is taken backup by CHT1Choline + acetateHistamineL-HistidineHDCPLPHistamineHNMTSAMNτ​-MethylhistamineNitric oxideL-ArgininenNOS (NOS1)NADPH, O2​, BH4​, FAD, FMN,heme; Ca2+​/calmodulinNO + L-citrullineSynthesis pathways of the main small-molecule neurotransmitters, phone layoutPrecursorNeurotransmitter or hormoneIntermediate or inactiveCatecholaminesL-TyrosineTH, rate-limitingBH4​, Fe2+​, O2​L-DOPAAADCPLP (vitamin B6 form)DopamineDBHCu, ascorbate, O2​NorepinephrinePNMTSAMEpinephrineSerotonin and melatoninL-TryptophanTPH1, TPH2, rate-limitingBH4​, Fe2+​, O2​5-HTPAADCPLPSerotoninAANATacetyl-CoAN-AcetylserotoninASMTSAMMelatoninGABAL-GlutamineGlutaminase (GLS)L-GlutamateGAD65, GAD67PLPGABAGABA-TPLPSuccinic semialdehydeAcetylcholineCholine + acetyl-CoAChATAcetylcholineAChEin the cleft; choline is taken back up byCHT1Choline + acetateHistamineL-HistidineHDCPLPHistamineHNMTSAMNτ​-MethylhistamineNitric oxideL-ArgininenNOS (NOS1)NADPH, O2​, BH4​, FAD, FMN, heme;Ca2+​/calmodulinNO + L-citrulline
Reactions and cofactors: UniProt entries listed under the neurotransmitter table (catalytic activity and cofactor fields), accessed October 29, 2026. Rate-limiting steps: Purves et al., Neuroscience 2nd ed., “The Biogenic Amines.” PLP as a vitamin B6 coenzyme: NIH Office of Dietary Supplements, Vitamin B6 fact sheet for health professionals, updated June 16, 2023.
Text version of the pathways
  • Catecholamines. L-tyrosine + BH4 + O2 → L-DOPA (tyrosine hydroxylase, Fe²⁺); L-DOPA → dopamine + CO2 (AADC, PLP); dopamine + 2 ascorbate + O2 → norepinephrine (DBH, Cu); norepinephrine + SAM → epinephrine (PNMT).
  • Serotonin and melatonin. L-tryptophan + BH4 + O2 → 5-hydroxytryptophan (TPH1 or TPH2, Fe²⁺); → serotonin + CO2 (AADC, PLP); serotonin + acetyl-CoA → N-acetylserotonin (AANAT, which sets the night–day rhythm of melatonin production in the pineal gland); N-acetylserotonin + SAM → melatonin (ASMT).
  • GABA. L-glutamine → L-glutamate (glutaminase); L-glutamate → GABA + CO2 (GAD65 or GAD67, PLP); GABA → succinic semialdehyde (GABA transaminase, PLP).
  • Acetylcholine. Choline + acetyl-CoA → acetylcholine + CoA (ChAT); acetylcholine + H2O → choline + acetate (AChE); the high-affinity transporter CHT1 brings choline into the terminal.
  • Histamine. L-histidine → histamine + CO2 (HDC, PLP); histamine + SAM → Nτ-methylhistamine (HNMT).
  • Nitric oxide. 2 L-arginine + 3 NADPH + 4 O2 → 2 L-citrulline + 2 NO (nNOS; heme, FAD, FMN and BH4 as cofactors).

Related Supplements A–Z entries: Vitamin B6, Choline, Melatonin, Vitamin C, Copper, Iron. Those pages cover the nutrients themselves; this page states only the enzyme chemistry.

Diet and supplements

Human studies and FDA labeling document specific links between diet and these pathways

The interactions below were measured in people or are stated in FDA-approved labeling. Mechanisms seen only in cells or animals are labeled as laboratory findings. None of this is advice to take or avoid a product.

At the published IC50 of 67 µM, caffeine would occupy half of brain A1 adenosine receptorsEducational calculation
Calculated fraction of human brain A1 adenosine receptors occupied by caffeine against plasma caffeine, using occupancy = C/(C + 67 micromolar); solid over the measured range of 0 to 9 mg/L, dashed where extrapolated0%25%50%75%100%A1 receptors occupied (calculated)050100150Plasma caffeine, µmol/L0510152025Plasma caffeine, mg/Loccupancy = C / (C + 67 µM), over the measured plasma range 0–9 mg/Lextrapolated beyond the measured plasma rangemeasured range0–9 mg/LextrapolatedIC50 about 67 µM (about 13 mg/L) gives 50%IC50​ ≈ 67 µM ≈ 13 mg/Lauthors' estimate: about 450 mg in a 70-kg adultCalculated fraction of human brain A1 adenosine receptors occupied by caffeine against plasma caffeine, using occupancy = C/(C + 67 micromolar); solid over the measured range of 0 to 9 mg/L, dashed where extrapolated0%25%50%75%100%A1 receptors occupied (calculated)050100150Plasma caffeine, µmol/L01020Plasma caffeine, mg/Loccupancy = C / (C + 67 µM), over the measured plasma range 0–9 mg/Lextrapolated beyond the measured plasma rangemeasured range0–9 mg/LextrapolatedIC50 about 67 µM (about 13 mg/L) gives 50%IC50​ = 67 µM≈ 13 mg/L
Calculated from the study's Equation 1, occupancy = C/(IC50 + C), with IC50 ≈ 67 µmol/L (≈ 13 mg/L) from Elmenhorst D, et al. J Nucl Med 2012;53:1723–1729; an educational calculation, not a measurement or a prediction for any product. The IC50 is an in vivo value from human PET: the plasma caffeine concentration giving half-maximal displacement of 18F-CPFPX from cerebral A1 receptors in 15 healthy men (16 scans), fitted at 12.5 mg/L (SE 1.5 mg/L) with maximal occupancy constrained to 100%. It is not an in vitro Ki. Measured plasma levels spanned 0–9 mg/L (solid line); the dashed line extrapolates, as the authors' own figure does. The highest measured occupancy was 44%, after 4.27 mg/kg intravenous caffeine. mg/L = µmol/L × 194.19/1,000 (caffeine molar mass, PubChem CID 2519).
Show data: calculated A1 receptor occupancy
Calculated fraction of brain A1 adenosine receptors occupied at selected plasma caffeine concentrations, occupancy = C/(67 µM + C)
Plasma caffeine, µmol/Lmg/LCalculated occupancyRange
101.913%Measured range
254.927%Measured range
46.39.041%Upper end of measured range
6713.050%Extrapolated
10019.460%Extrapolated
15029.169%Extrapolated
Documented interactions between diet or supplements and neurotransmitter pathways, with the type of evidence
InteractionWhat was foundEvidence
Caffeine and adenosine receptors (Caffeine)Caffeine is a nonselective adenosine receptor antagonist. In 15 healthy men, PET with 18F-CPFPX showed caffeine displacing 5–44% of A1 receptor binding, with half-maximal displacement at 67 µM plasma caffeine, which the authors equate to about 450 mg in a 70-kg adult or about 4.5 cups of coffee. They estimate that repeated beverages over a day might occupy up to 50% of brain A1 receptors.Human PET study
Protein or carbohydrate meals and the tryptophan ratioThe large neutral amino acids share one competitive transporter at the blood–brain barrier. In 8 adults who ate both test breakfasts, the plasma tryptophan to large-neutral-amino-acid ratio differed by a median 54% (range 36–88%) between a carbohydrate-rich and a protein-rich breakfast, and the tyrosine ratio by 28% (10–64%). Brain uptake itself was not measured; the authors wrote that brain tryptophan “probably” follows.Human plasma data
Vitamin B6 and levodopa (Vitamin B6)FDA-approved labeling for carbidopa–levodopa states that pyridoxine hydrochloride in oral doses of 10–25 mg may reverse the effects of levodopa given alone by increasing the rate of aromatic amino acid decarboxylation, and that carbidopa inhibits this action.FDA-approved label
Dietary protein and levodopa absorptionThe same label states that levodopa competes with certain amino acids for transport across the gut wall, so its absorption may be impaired in some patients on a high-protein diet.FDA-approved label
Tyramine and monoamine oxidase inhibitorsMAO inhibitors prevent the breakdown of tyramine from food, drinks and some medicines; high tyramine can cause a sudden rise in blood pressure, the tyramine pressor response. Dopamine and tyramine are metabolized by both MAO-A and MAO-B.Clinical review (StatPearls)
L-DOPA and the LAT1 transporterL-DOPA uptake by a mouse brain capillary endothelial cell line had the characteristics of 4F2hc/LAT1, and immunostaining found LAT1 mainly in CNS microvessels.Laboratory finding (cell line, tissue staining)

Elmenhorst et al. 2012; Fernstrom JD. Amino Acids 2013;45:419–430; Wurtman RJ, et al. Am J Clin Nutr 2003;77:128–132; SINEMET (carbidopa and levodopa) tablets, prescribing information, Organon LLC, DailyMed set ID 9b17b028-964a-473c-823d-81423535bd66 (published August 24, 2026); Patel P, Saadabadi A. Monoamine Oxidase Inhibitors (MAOIs). StatPearls, updated December 13, 2025; Kageyama T, et al. Brain Res 2000;879:115–121. Related entry: Melatonin (made from serotonin in the pineal gland).

Blood–brain barrier

Brain capillaries are sealed by tight junctions, lined with efflux pumps and wrapped by pericytes and astrocyte endfeet

Brain capillary endothelial cells differ from those elsewhere in three ways: tight junctions close the gaps between them, they have no fenestrations, and they lack pinocytic activity. Pericytes share their basement membrane, and astrocyte endfeet cover close to 99% of the outer capillary surface. The physicochemical rules of thumb for passive entry are on the ADME, PK and PBPK page.

A brain capillary in cross-section, with the tight junction enlargedSchematic, not to scale
Cross-section of a brain capillary: endothelial cells sealed by tight junctions, basement membrane, pericyte and astrocyte endfeet; schematic, not to scaleBlood12345671Capillary lumen, carrying blood.2Endothelial cells: no fenestrations and a lack of pinocytic activity;P-gp and BCRP pump substrates back into the blood.3Tight junctions seal the gap between endothelial cells (detail atright).4Basement membrane, shared by endothelial cells and pericytes.5Pericyte, in the basement membrane; peg-and-socket contactswith the endothelium (N-cadherin, connexins).6Astrocyte endfeet cover close to 99% of the capillary's outersurface.7Astrocyte cell body; its processes end in the endfeet.Tight junction, detailZOactinClaudin-5, occludin and JAMsbridge the gap between the twocell membranesZO-1, ZO-2, ZO-3 link them toactin filaments inside each cellCross-section of a brain capillary, phone layout with numbered key; schematic, not to scaleBlood12345671Capillary lumen, carrying blood.2Endothelial cells: no fenestrations and a lack ofpinocytic activity; P-gp and BCRP pump substratesback into the blood.3Tight junctions seal the gap between endothelial cells(detail at right).4Basement membrane, shared by endothelial cells andpericytes.5Pericyte, in the basement membrane; peg-and-socketcontacts with the endothelium (N-cadherin,connexins).6Astrocyte endfeet cover close to 99% of thecapillary's outer surface.7Astrocyte cell body; its processes end in the endfeet.Tight junction, detailZOactinClaudin-5, occludin andJAMs bridge the gapbetween the two cellmembranesZO-1, ZO-2, ZO-3 linkthem to actin filamentsinside each cell
Kadry H, Noorani B, Cucullo L. Fluids Barriers CNS 2020;17:69; UniProt CLDN5 O00501, OCLN Q16625, TJP1 Q07157. Real capillary walls are far thinner relative to the lumen than drawn; two endothelial cells are drawn so that their junctions can be shown.

Claudins bind claudins on the neighboring cell to form the primary seal; in brain endothelium claudin-1 and claudin-5 with occludin are the main tight-junction proteins.

Explanation, details and sources
  • Tight junctions. Built from three integral membrane proteins, claudins, occludin and junctional adhesion molecules (JAMs), and cytoplasmic proteins including ZO-1, ZO-2 and ZO-3 that link them to actin. Mice genetically lacking claudin-5 had a severely leaky blood–brain barrier and died shortly after birth (animal finding); occludin-deficient mice were viable with intact barriers.
  • Endothelial cells. No fenestrations, a lack of pinocytic activity, and ATP-driven efflux pumps on the blood-facing (luminal) membrane. The luminal and abluminal membranes are about 500 nm apart or less.
  • Pericytes. Most abundant in the CNS; they share the basement membrane with endothelial cells and make peg-and-socket contacts with them through N-cadherin and connexins.
  • Astrocytes. Their foot processes cover close to 99% of the abluminal capillary surface and form the interface between the vessel and the neural tissue.
  • Estimate of the barrier's reach. Pardridge estimated that the blood–brain barrier excludes about 100% of large-molecule drugs and more than 98% of small-molecule drugs from the brain.

Kadry et al. 2020; UniProt O00501 (claudin-5: tight junction-specific obliteration of the intercellular space), Q07157 (ZO-1); Pardridge WM. NeuroRx 2005;2:3–14.

Transport

Small lipophilic molecules diffuse in; nutrients need carriers, large proteins need receptors, and efflux pumps send many drugs back

Lipid-soluble molecules under about 400 Da that form fewer than 8 hydrogen bonds can cross the endothelium by free diffusion. Glucose, amino acids and other nutrients use solute carriers, and larger molecules such as insulin, leptin and iron-loaded transferrin are taken up by receptor-mediated endocytosis.

Six routes across the brain endothelium; the paracellular route is closedSchematic, not to scale
Six routes across the brain capillary endothelium: paracellular (blocked), passive diffusion, carrier-mediated transport, receptor-mediated transcytosis, adsorptive-mediated transcytosis and active efflux; schematicBlood sideBrain sideEndothelial cell1ParacellularClosed to polar,water-solublemolecules by tightjunctions2Passive diffusionSmall lipophilicmolecules, under about400 Da and with fewerthan 8 hydrogen bonds3Carrier-mediatedGLUT1: glucose. LAT1:large neutral aminoacids and L-DOPA.MCT1: lactate. ENT1 andCNTs: nucleosides4Receptor-mediatedtranscytosisTransferrin receptor(iron-loadedtransferrin); insulinreceptor5Adsorptive-mediatedtranscytosisPositively charged largemolecules bindcell-surface sites6Active effluxP-gp (ABCB1) and BCRP(ABCG2) on the bloodside; MRPs on eithersideSix routes across the brain capillary endothelium, phone layout; schematic1ParacellularClosed to polar, water-soluble moleculesby tight junctions2Passive diffusionSmall lipophilic molecules, under about 400Da and with fewer than 8 hydrogen bonds3Carrier-mediatedGLUT1: glucose. LAT1: large neutral aminoacids and L-DOPA. MCT1: lactate. ENT1and CNTs: nucleosides4Receptor-mediated transcytosisTransferrin receptor (iron-loadedtransferrin); insulin receptor5Adsorptive-mediated transcytosisPositively charged large molecules bindcell-surface sites6Active effluxP-gp (ABCB1) and BCRP (ABCG2) on theblood side; MRPs on either sideBlood
Kadry et al. 2020; Pardridge WM. J Cereb Blood Flow Metab 2012;32:1959–1972; Barar J, et al. BioImpacts 2016;6:225–248; UniProt SLC2A1 P11166, SLC7A5 Q01650, SLC16A1 P53985, SLC29A1 Q99808, TFRC P02786, INSR P06213, ABCB1 P08183, ABCG2 Q9UNQ0, ABCC1 P33527.
Text version of the routes
  1. ParacellularTight junctions prevent unregulated passage of polar, water-soluble molecules between endothelial cells.
  2. Passive transcellular diffusionSmall lipid-soluble molecules, molecular weight below 400 Da and fewer than 8 hydrogen bonds. Above 400 Da, permeability no longer rises in proportion to lipid solubility.
  3. Carrier-mediated transportGLUT1 carries glucose and is the brain's most important energy carrier at the barrier; LAT1 (with 4F2hc) exchanges large neutral amino acids and carries L-DOPA; MCT1 carries lactate, pyruvate and ketone bodies; ENT1 and the concentrative nucleoside transporters carry nucleosides such as adenosine.
  4. Receptor-mediated transcytosisA ligand binds its receptor, is taken into a vesicle and released on the brain side: transferrin by the transferrin receptor, insulin by the insulin receptor.
  5. Adsorptive-mediated transcytosisPositively charged large molecules bind cell-surface sites that trigger endocytosis and transcytosis.
  6. Active effluxP-gp (ABCB1) and BCRP (ABCG2) sit on the luminal membrane and pump substrates from the endothelium back into blood, with overlapping substrates; MRPs (ABCC family) appear on either the luminal or the abluminal membrane and favor water-soluble conjugates as substrates.

Circumventricular organs are midline structures around the third and fourth ventricles; most of them lack a blood–brain barrier (the subcommissural organ is usually described as the exception). They are sites of communication with the cerebrospinal fluid and, through blood-borne products, between the brain and peripheral organs.

Circumventricular organs, their type, and whether they contain neurons
Circumventricular organTypeNeurons present
Subfornical organSensoryYes
Area postremaSensoryYes
Organum vasculosum of the lamina terminalisSensoryYes
Pineal glandSecretoryNo
Median eminenceSecretoryNo
Neurohypophysis (posterior pituitary)SecretoryNo
Subcommissural organSecretoryYes

Kaur C, Ling EA. Histol Histopathol 2017;32:879–892 (abstract).

Measurement

Brain penetration is measured as an unbound concentration ratio or, in people, as receptor occupancy by PET

A total brain-to-blood ratio mixes barrier transport with binding to brain tissue and plasma proteins. The unbound ratio Kp,uu isolates what the barrier does, and positron emission tomography (PET) shows how much of a target a compound occupies in a living human brain.

Total ratios (Hammarlund-Udenaes et al. 2008)logBB = log10(Cbrain / Cblood) at a stated time, not necessarily at steady state  Kp = Cbrain / Cplasma, total concentrations
Unbound ratio at steady stateKp,uu = Cu,brain ISF / Cu,plasma
Measured Kp,uu values in rats range from 0.022 for baclofen to 3.03 for oxycodone, about 150-foldPublished rat data
Published unbound brain-to-plasma concentration ratios (Kp,uu) in rats for eleven measurements of eight drugs, on a logarithmic scale from 0.01 to 10, with the passive-equilibrium line at 1below 1: net active effluxabove 1:net active influxOxycodone (Boström et al. 2006)Oxycodone: Kp,uu 3.03 (0.038) (Boström et al. 2006; rat)3.03YM992 (Mano et al. 2002)YM992: Kp,uu 1.42 ± 0.81 (Mano et al. 2002; rat)1.42Codeine (Xie and Hammarlund-Udenaes 1998)Codeine: Kp,uu 1.06 ± 0.12 (Xie and Hammarlund-Udenaes 1998; rat)1.06Morphine (Stain-Texier et al. 1999)Morphine: Kp,uu 0.51 ± 0.18 (Stain-Texier et al. 1999; rat)0.51Morphine (Tunblad et al. 2003)Morphine: Kp,uu 0.29 ± 0.07 (Tunblad et al. 2003; rat)0.29M6G (Stain-Texier et al. 1999)M6G: Kp,uu 0.56 ± 0.18 (Stain-Texier et al. 1999; rat)0.56M6G (Tunblad et al. 2005)M6G: Kp,uu 0.29 (Tunblad et al. 2005; rat)0.29M6G (Bouw et al. 2001)M6G: Kp,uu 0.22 ± 0.09 (Bouw et al. 2001; rat)0.22Gabapentin (Wang and Welty 1996)Gabapentin: Kp,uu 0.12 (Wang and Welty 1996; rat)0.12M3G (Xie et al. 2000)M3G: Kp,uu 0.08 ± 0.02 (Xie et al. 2000; rat)0.08Baclofen (Deguchi et al. 1995)Baclofen: Kp,uu 0.022 (Deguchi et al. 1995; rat)0.0220.010.1110Kp,uu​ (unbound brain ISF / unbound plasma), log scalePublished unbound brain-to-plasma concentration ratios (Kp,uu) in rats for eleven measurements of eight drugs, on a logarithmic scale from 0.01 to 10, with the passive-equilibrium line at 1below 1: net active effluxabove 1:net active influxOxycodone (Boström et al. 2006)Oxycodone: Kp,uu 3.03 (0.038) (Boström et al. 2006; rat)3.03YM992 (Mano et al. 2002)YM992: Kp,uu 1.42 ± 0.81 (Mano et al. 2002; rat)1.42Codeine (Xie and Hammarlund-Udenaes 1998)Codeine: Kp,uu 1.06 ± 0.12 (Xie and Hammarlund-Udenaes 1998; rat)1.06Morphine (Stain-Texier et al. 1999)Morphine: Kp,uu 0.51 ± 0.18 (Stain-Texier et al. 1999; rat)0.51Morphine (Tunblad et al. 2003)Morphine: Kp,uu 0.29 ± 0.07 (Tunblad et al. 2003; rat)0.29M6G (Stain-Texier et al. 1999)M6G: Kp,uu 0.56 ± 0.18 (Stain-Texier et al. 1999; rat)0.56M6G (Tunblad et al. 2005)M6G: Kp,uu 0.29 (Tunblad et al. 2005; rat)0.29M6G (Bouw et al. 2001)M6G: Kp,uu 0.22 ± 0.09 (Bouw et al. 2001; rat)0.22Gabapentin (Wang and Welty 1996)Gabapentin: Kp,uu 0.12 (Wang and Welty 1996; rat)0.12M3G (Xie et al. 2000)M3G: Kp,uu 0.08 ± 0.02 (Xie et al. 2000; rat)0.08Baclofen (Deguchi et al. 1995)Baclofen: Kp,uu 0.022 (Deguchi et al. 1995; rat)0.0220.010.1110Kp,uu​, log scale
Kp,uu,brain values in rats as compiled in Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. Pharm Res 2008;25:1737–1750, Table III, from the original studies named in each label (mostly microdialysis). Interpretation of 1, below 1 and above 1 from the same paper. M6G, morphine-6-glucuronide; M3G, morphine-3-glucuronide; YM992, an investigational antidepressant; ISF, interstitial fluid. Values from different studies and methods are not directly comparable, and rat values are not human values.
Show data: Kp,uu in rats
Unbound brain interstitial fluid to unbound plasma concentration ratios in rats, as printed in Hammarlund-Udenaes et al. 2008, Table III
DrugKp,uu as printedOriginal study
Oxycodone3.03 (0.038)Boström et al. 2006
YM9921.42 ± 0.81Mano et al. 2002
Codeine1.06 ± 0.12Xie and Hammarlund-Udenaes 1998
Morphine0.51 ± 0.18Stain-Texier et al. 1999
Morphine0.29 ± 0.07Tunblad et al. 2003
M6G0.56 ± 0.18Stain-Texier et al. 1999
M6G0.29Tunblad et al. 2005
M6G0.22 ± 0.09Bouw et al. 2001
Gabapentin0.12Wang and Welty 1996
M3G0.08 ± 0.02Xie et al. 2000
Baclofen0.022Deguchi et al. 1995

Among CNS-active drugs Kp,uu differs by up to 150-fold, total Kp (logBB) by at least 2,000-fold and barrier permeability by at least 20,000-fold.

In human PET studies, chlorpheniramine and diphenhydramine occupied about half or more of brain H1 receptors; fexofenadine's occupancy was negligiblePublished human PET data
Brain histamine H1 receptor occupancy measured by PET with carbon-11 doxepin after single doses of antihistamines in healthy adults or allergic-rhinitis patientscomparator drugcalled second-generation or non-sedating(+)-Chlorpheniramine 5 mg IV(+)-Chlorpheniramine 5 mg IV: 98.2% ± 1.2 (97.0 to 99.4) (Yanai 1995)98.2%(+)-Chlorpheniramine 2 mg(+)-Chlorpheniramine 2 mg: 76.8% ± 4.2 (72.6 to 81.0) (Yanai 1995)76.8%Diphenhydramine 30 mgDiphenhydramine 30 mg: 56.4% (Tashiro 2008)56.4%d-Chlorpheniramine 2 mgd-Chlorpheniramine 2 mg: 53% ± 33.2 (19.8 to 86.2) (Kubo 2011)53%Cetirizine 20 mgCetirizine 20 mg: 26% (Tashiro 2004)26%Terfenadine 60 mgTerfenadine 60 mg: 17.2% ± 14.2 (3.0 to 31.4) (Yanai 1995)17.2%Bepotastine 10 mgBepotastine 10 mg: 14.7% (Tashiro 2008)14.7%Loratadine 10 mgLoratadine 10 mg: 11.7% ± 19.5 (−7.8 to 31.2) (Kubo 2011)11.7%Ebastine 10 mgEbastine 10 mg: 10% approximately (Tagawa 2001)≈10%Levocetirizine 5 mgLevocetirizine 5 mg: 8.1% 95% CI -9.8 to 26 (Hiraoka 2015)8.1%Fexofenadine 120 mgFexofenadine 120 mg: -0.1% (Tashiro 2004)−0.1%Fexofenadine 60 mgFexofenadine 60 mg: -8% 95% CI -26.7 to 10.6 (Hiraoka 2015)−8%−25%0%25%50%75%100%Brain H1 receptor occupancyBrain histamine H1 receptor occupancy measured by PET with carbon-11 doxepin after single doses of antihistamines in healthy adults or allergic-rhinitis patientscomparator drugcalled second-generation or non-sedating(+)-Chlorpheniramine 5 mg IV(+)-Chlorpheniramine 5 mg IV: 98.2% ± 1.2 (97.0 to 99.4) (Yanai 1995)98.2%(+)-Chlorpheniramine 2 mg(+)-Chlorpheniramine 2 mg: 76.8% ± 4.2 (72.6 to 81.0) (Yanai 1995)76.8%Diphenhydramine 30 mgDiphenhydramine 30 mg: 56.4% (Tashiro 2008)56.4%d-Chlorpheniramine 2 mgd-Chlorpheniramine 2 mg: 53% ± 33.2 (19.8 to 86.2) (Kubo 2011)53%Cetirizine 20 mgCetirizine 20 mg: 26% (Tashiro 2004)26%Terfenadine 60 mgTerfenadine 60 mg: 17.2% ± 14.2 (3.0 to 31.4) (Yanai 1995)17.2%Bepotastine 10 mgBepotastine 10 mg: 14.7% (Tashiro 2008)14.7%Loratadine 10 mgLoratadine 10 mg: 11.7% ± 19.5 (−7.8 to 31.2) (Kubo 2011)11.7%Ebastine 10 mgEbastine 10 mg: 10% approximately (Tagawa 2001)≈10%Levocetirizine 5 mgLevocetirizine 5 mg: 8.1% 95% CI -9.8 to 26 (Hiraoka 2015)8.1%Fexofenadine 120 mgFexofenadine 120 mg: -0.1% (Tashiro 2004)−0.1%Fexofenadine 60 mgFexofenadine 60 mg: -8% 95% CI -26.7 to 10.6 (Hiraoka 2015)−8%−25%0%25%50%75%100%Brain H1 receptor occupancy
All studies used 11C-doxepin PET after single doses: Yanai K, et al. Br J Pharmacol 1995;116:1649–1655 (frontal cortex, 20 healthy men across groups); Tagawa M, et al. Br J Clin Pharmacol 2001;52:501–509; Tashiro M, et al. J Clin Pharmacol 2004;44:890–900; Tashiro M, et al. Br J Clin Pharmacol 2008;65:811–821; Kubo N, et al. Hum Psychopharmacol 2011;26:133–139 (11 men with allergic rhinitis); Hiraoka K, et al. Expert Opin Drug Saf 2015;14:199–206. Rose points: comparator drugs in their studies; teal: drugs the studies called second-generation or non-sedating. Whiskers: the ± spread or 95% CI each study reported (the abstracts do not say whether ± is SD or SEM); points without whiskers were reported as means only. Results from different studies and regions are not directly comparable.
Show data: brain H1 receptor occupancy by antihistamine
Brain histamine H1 receptor occupancy after single doses of antihistamines, human PET with carbon-11 doxepin
Drug and doseOccupancySpread reportedStudy
(+)-Chlorpheniramine 5 mg intravenous98.2%± 1.2Yanai 1995
(+)-Chlorpheniramine 2 mg oral76.8%± 4.2Yanai 1995
Diphenhydramine 30 mg56.4%mean of 8 menTashiro 2008
d-Chlorpheniramine 2 mg53.0%± 33.2Kubo 2011
Cetirizine 20 mg26.0%meanTashiro 2004
Terfenadine 60 mg17.2%± 14.2Yanai 1995
Bepotastine 10 mg14.7%mean of 8 menTashiro 2008
Loratadine 10 mg11.7%± 19.5Kubo 2011
Ebastine 10 mgabout 10%approximateTagawa 2001
Levocetirizine 5 mg8.1%95% CI −9.8 to 26.0Hiraoka 2015
Fexofenadine 120 mg−0.1%meanTashiro 2004
Fexofenadine 60 mg−8.0%95% CI −26.7 to 10.6Hiraoka 2015
Documented examples in people of compounds that do or do not reach the brain
CompoundReaches the brain?What shows it
LoperamideNot at usual doses; yes when P-gp is inhibitedIn 8 healthy men, 16 mg loperamide alone caused no respiratory depression; with 600 mg quinidine, a P-gp inhibitor, it did (P <.001), and plasma loperamide did not explain the change. That loperamide is a P-gp substrate came from in vitro studies.
Dopamine, levodopa, carbidopaDopamine no; levodopa yes; carbidopa noFDA-approved labeling: dopamine does not cross the blood–brain barrier, its precursor levodopa does, and carbidopa, which blocks peripheral decarboxylation of levodopa, does not cross and does not affect levodopa metabolism in the brain.
AntihistaminesDiphenhydramine and chlorpheniramine occupied about half or more of brain H1 receptors; fexofenadine's occupancy was negligibleHuman PET occupancy of brain H1 receptors (figure above).
CaffeineYesConcentration-dependent displacement of an A1 receptor PET tracer after intravenous caffeine in 15 healthy men.

Sadeque AJM, et al. Clin Pharmacol Ther 2000;68:231–237; SINEMET prescribing information (DailyMed, 2026); Elmenhorst et al. 2012. Related: CNS MPO score and property rules; pharmacokinetic equations.

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.